Cargando…

Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment

(1) Inverse psoriasis (IP), also known as intertriginous, typically affects the groin, armpits, navel, intergluteal fissure, and external genitalia. Skin lesions are erythematous plaques of inflammatory nature, smooth, well-delimited, non-scaly, and non-infiltrated. Lesions may be accompanied by itc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietrangelo, Laura, Dattola, Annunziata, Magnifico, Irene, Petronio Petronio, Giulio, Cutuli, Marco Alfio, Venditti, Noemi, Guarnieri, Antonio, Wollenberg, Andreas, Pellacani, Giovanni, Di Marco, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094358/
https://www.ncbi.nlm.nih.gov/pubmed/37047310
http://dx.doi.org/10.3390/ijms24076339
_version_ 1785023822694449152
author Pietrangelo, Laura
Dattola, Annunziata
Magnifico, Irene
Petronio Petronio, Giulio
Cutuli, Marco Alfio
Venditti, Noemi
Guarnieri, Antonio
Wollenberg, Andreas
Pellacani, Giovanni
Di Marco, Roberto
author_facet Pietrangelo, Laura
Dattola, Annunziata
Magnifico, Irene
Petronio Petronio, Giulio
Cutuli, Marco Alfio
Venditti, Noemi
Guarnieri, Antonio
Wollenberg, Andreas
Pellacani, Giovanni
Di Marco, Roberto
author_sort Pietrangelo, Laura
collection PubMed
description (1) Inverse psoriasis (IP), also known as intertriginous, typically affects the groin, armpits, navel, intergluteal fissure, and external genitalia. Skin lesions are erythematous plaques of inflammatory nature, smooth, well-delimited, non-scaly, and non-infiltrated. Lesions may be accompanied by itching, pain, or burning sensation. The aim of this study is both to investigate the modulation of the skin microbiota induced by IP and, on the other hand, to test the effectiveness of the new biotechnological product LimpiAL 2.5%. (2) Patients affected by IP were recruited in a private practice and treated for 4 weeks with LimpiAL 2.5% exclusively. The clinical effects on the lesion skin were evaluated, and the skin microbiotas before and after treatment were compared. (3) The clinical outcomes reveled a significant beneficial effect of the tested product. At the same time, LimpiAL increased the biological diversity of the skin microbiota and exerted a significant decrease of some Corynebacterium species, and the increase of some Staphylococcus species. (4) Together, the clinical outcomes and the microbiota analysis suggest that LimpiAL treatment improves the skin condition of affected patients, basically restoring the eubiosis conditions of the affected sites and modulating the bacterial composition of the resident microbiota.
format Online
Article
Text
id pubmed-10094358
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100943582023-04-13 Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment Pietrangelo, Laura Dattola, Annunziata Magnifico, Irene Petronio Petronio, Giulio Cutuli, Marco Alfio Venditti, Noemi Guarnieri, Antonio Wollenberg, Andreas Pellacani, Giovanni Di Marco, Roberto Int J Mol Sci Article (1) Inverse psoriasis (IP), also known as intertriginous, typically affects the groin, armpits, navel, intergluteal fissure, and external genitalia. Skin lesions are erythematous plaques of inflammatory nature, smooth, well-delimited, non-scaly, and non-infiltrated. Lesions may be accompanied by itching, pain, or burning sensation. The aim of this study is both to investigate the modulation of the skin microbiota induced by IP and, on the other hand, to test the effectiveness of the new biotechnological product LimpiAL 2.5%. (2) Patients affected by IP were recruited in a private practice and treated for 4 weeks with LimpiAL 2.5% exclusively. The clinical effects on the lesion skin were evaluated, and the skin microbiotas before and after treatment were compared. (3) The clinical outcomes reveled a significant beneficial effect of the tested product. At the same time, LimpiAL increased the biological diversity of the skin microbiota and exerted a significant decrease of some Corynebacterium species, and the increase of some Staphylococcus species. (4) Together, the clinical outcomes and the microbiota analysis suggest that LimpiAL treatment improves the skin condition of affected patients, basically restoring the eubiosis conditions of the affected sites and modulating the bacterial composition of the resident microbiota. MDPI 2023-03-28 /pmc/articles/PMC10094358/ /pubmed/37047310 http://dx.doi.org/10.3390/ijms24076339 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pietrangelo, Laura
Dattola, Annunziata
Magnifico, Irene
Petronio Petronio, Giulio
Cutuli, Marco Alfio
Venditti, Noemi
Guarnieri, Antonio
Wollenberg, Andreas
Pellacani, Giovanni
Di Marco, Roberto
Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment
title Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment
title_full Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment
title_fullStr Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment
title_full_unstemmed Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment
title_short Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment
title_sort efficacy and microbiota modulation induced by limpial 2.5%, a new medical device for the inverse psoriasis treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094358/
https://www.ncbi.nlm.nih.gov/pubmed/37047310
http://dx.doi.org/10.3390/ijms24076339
work_keys_str_mv AT pietrangelolaura efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment
AT dattolaannunziata efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment
AT magnificoirene efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment
AT petroniopetroniogiulio efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment
AT cutulimarcoalfio efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment
AT vendittinoemi efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment
AT guarnieriantonio efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment
AT wollenbergandreas efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment
AT pellacanigiovanni efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment
AT dimarcoroberto efficacyandmicrobiotamodulationinducedbylimpial25anewmedicaldevicefortheinversepsoriasistreatment